Janssen strikes licensing deal for investigational Alzheimer's treatment

|By:, SA News Editor

Janssen Pharmaceuticals (JNJ +0.6%) inks a new development and commercialization deal with Finland's Orion Corp. for the latter's alpha-2c adrenoceptor antagonists including ORM-12741.

Orion gets a $31M upfront payment and is eligible for milestone payments and royalties — the company will use the upfront cash to help fund the Phase 2a study of ORM-12741.

ORM-12741 (which Janssen will have the right to commercialize outside of Europe) is being tested as a possible treatment for "the cognitive and behavioral symptoms related to Alzheimer's." (PR)